Obstetrics and Gynecology
Arti Sharma; Yashika Pehal; Namrata Saxena; Swati Agrawal
Articles in Press, Accepted Manuscript, Available Online from 31 January 2024
Abstract
Background and Objective: Iron deficiency anemia is a major public health problem worldwide. Oral iron intake is preferred, but parenteral administration of iron is necessary under certain circumstances. The objective of the present study is to compare the efficacy and safety of parenteral Iron Sucrose ...
Read More
Background and Objective: Iron deficiency anemia is a major public health problem worldwide. Oral iron intake is preferred, but parenteral administration of iron is necessary under certain circumstances. The objective of the present study is to compare the efficacy and safety of parenteral Iron Sucrose to Ferric Carboxymaltose (FCM) in improving the hematological indices in anemic pregnant women.
Methods: The study was a comparative, observational study conducted at the Department of Obstetrics and Gynecology, SGRR Institute of Health and Medical Sciences, Dehradun from September 2018 to May 2020. The sample size was 120 pregnant women with iron deficiency anemia in each group. One group was treated with intravenous Iron Sucrose and the other group was treated with intravenous FCM. The outcome measures were improvement in hematological parameters and experienced side effects. Data was analyzed by using appropriate statistical tests.
Results: Both groups were comparable in terms of baseline parameters. Hemoglobin rise was rapid in the group treated with FCM (8.7 ± 0.47 g/dl to 11.6 ± 0.77 g/dl) than the iron sucrose (8.24 ± 0.57 g/dl to 10.60 ± 0.87g/dl) group. Rise in serum ferritin and MCV of RBC were also higher in FCM group than the iron sucrose group. Both groups have only mild side effects.
Conclusion: Hence we can conclude from our study that parenteral therapy with iron sucrose and FCM, both can successfully treat iron deficiency anemia in pregnancy but the improvement is faster, safer, and more convenient with the use of FCM than iron sucrose.
Nafiseh Ansarinejad; Bahareh Abbasi; Maryam Sadat Sadat Rasul; Farshid Fardad; Tayeb Ramim
Volume 1, Issue 2 , September and October 2016
Abstract
Background: Anemia is prevalent in 32% to 60% of patients with cancer due to an underlying disease, nutritional deficiencies and complications of medication used in chemotherapy. National Comprehensive Cancer Network (NCCN) recommends the use of oral or intravenous iron supplementation in patients with ...
Read More
Background: Anemia is prevalent in 32% to 60% of patients with cancer due to an underlying disease, nutritional deficiencies and complications of medication used in chemotherapy. National Comprehensive Cancer Network (NCCN) recommends the use of oral or intravenous iron supplementation in patients with iron deficiency anemia.
